Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Children With Active Eosinophilic Esophagitis
NCT07112378Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in eosinophilic esophagitis (EoE), sponsored by Regeneron Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT07112378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07112378.